Metastatic prostate cancer occurs when cancer cells from the prostate spread to other parts of the body, most commonly to bones, lymph nodes, and sometimes to organs like the liver or lungs. While this advanced stage cannot be cured, treatment can control the disease for months or even years, helping men manage symptoms and maintain quality of life.

How Treatment Can Help Control Advanced Prostate Cancer

When prostate cancer spreads beyond the prostate gland to distant parts of the body, doctors focus on treatments that aim to slow the cancer’s growth, relieve symptoms, and help patients live as well and as long as possible. The main goal is not to eliminate the cancer completely, because metastatic prostate cancer cannot be cured, but rather to keep it under control for as long as possible.^[1][2]

Treatment decisions depend on several important factors. These include where the cancer has spread, how fast it appears to be growing, the patient’s overall health and age, what symptoms are present, and whether the patient has received treatment for prostate cancer in the past. The cancer’s response to hormones also plays a crucial role in choosing the right approach. Medical teams consider all these elements when recommending a treatment plan tailored to each individual.^[2][7]

There are established treatments that medical societies and healthcare organizations have approved and recommended based on years of research and clinical experience. At the same time, researchers continue to explore new therapies through clinical trials, testing innovative approaches that may become tomorrow’s standard treatments. This means patients today have access not only to proven options but also to experimental therapies that might offer additional benefits.^[2][11]

Standard Treatment Approaches

Hormone therapy, also called androgen deprivation therapy (ADT), is the foundation of treatment for metastatic prostate cancer. Prostate cancer cells need testosterone, a male hormone, to grow and multiply. Hormone therapy works by either blocking the body’s production of testosterone or preventing testosterone from reaching cancer cells. When the level of testosterone in the blood drops to very low levels (called the castrate level), cancer growth often slows dramatically.^[5][10]

The most common form of hormone therapy involves injections of drugs called LHRH agonists, such as goserelin (brand name Zoladex) or leuprolide (brand name Lupron). These medications work by signaling the brain to stop telling the testicles to make testosterone. Another option is an LHRH antagonist called degarelix (brand name Firmagon), which works faster to lower testosterone levels. Some men may also have surgery to remove the testicles, called an orchiectomy, which permanently stops testosterone production.^[14][10]

In recent years, medical guidelines have changed significantly. Doctors no longer recommend using hormone therapy alone for most men with metastatic prostate cancer. Instead, current recommendations call for combining hormone therapy with other drugs from the start of treatment. This approach, called combination therapy or doublet therapy (when two drugs are used together) or triplet therapy (when three drugs are combined), has been shown in clinical trials to help men live longer than hormone therapy alone.^[10][23]

One common combination adds drugs called androgen receptor signaling inhibitors (ARSIs) to standard hormone therapy. These medications, including apalutamide (brand name Erleada), enzalutamide (brand name Xtandi), and darolutamide (brand name Nubeqa), work differently than standard hormone therapy. They block testosterone from attaching to receptors on cancer cells, preventing the hormone from telling the cells to grow. Even when testosterone levels are already very low from standard hormone therapy, these drugs provide an additional layer of protection against cancer growth.^[11][14]

For men whose cancer is more aggressive or has spread to many places in the body, doctors may recommend adding chemotherapy to hormone therapy. The most commonly used chemotherapy drug is docetaxel (brand name Taxotere), which is given through an IV infusion, usually once every three weeks. Chemotherapy works by attacking rapidly dividing cells, including cancer cells. When combined with hormone therapy, it has been shown to extend survival significantly. Docetaxel is often given along with a steroid medication called prednisone, which helps reduce side effects and may have some anti-cancer effects of its own.^[11][14]

The duration of hormone therapy is typically long-term or lifelong, as stopping treatment often allows the cancer to begin growing again. The combination drugs may also be continued for extended periods, with adjustments made based on how well the cancer is responding and what side effects occur. Chemotherapy, when used, is usually given for a fixed number of cycles, commonly six cycles over approximately four to five months.^[11]

Radiation therapy may also play a role in treating metastatic prostate cancer, even though the cancer has spread. External beam radiation can be used to treat the prostate gland itself in men who still have it, which research has shown may help some men live longer. Radiation is also very effective for relieving pain when cancer has spread to specific bones. It can prevent or treat complications like urinary problems caused by the tumor pressing on the urethra. A typical course of radiation might involve daily treatments over several weeks, though shorter schedules are sometimes used for bone pain relief.^[14][16]

For men whose cancer has spread extensively to bones, a special type of internal radiation called radioisotope therapy may be recommended. The most commonly used agent is radium-223 dichloride (brand name Xofigo). This radioactive substance is given through an IV injection and travels through the bloodstream to areas where cancer is growing in bone. It delivers radiation directly to cancer cells while sparing most healthy tissue. Treatment typically involves six monthly injections.^[14][11]

Additional treatments focus on protecting bones and managing complications. Drugs called bisphosphonates, such as zoledronic acid (brand name Zometa), and a medication called denosumab (brand name Xgeva) help strengthen bones and reduce the risk of fractures and bone pain. These are given as injections, typically monthly. Steroid medications like prednisone or dexamethasone may be used to reduce inflammation, improve appetite, and provide pain relief.^[14]

Side effects vary depending on which treatments are used. Hormone therapy commonly causes hot flashes, fatigue, loss of sex drive, erectile dysfunction, weight gain, mood changes, and over time can lead to bone thinning and increased risk of heart problems. The newer hormone drugs like enzalutamide and apalutamide may cause fatigue, diarrhea, high blood pressure, and rarely, seizures. Chemotherapy side effects include hair loss, nausea, increased risk of infection due to low blood counts, fatigue, and numbness or tingling in hands and feet. Radiation can cause fatigue and skin irritation in the treated area, and when used for the prostate may cause urinary or bowel problems.^[11]

Treatment When Cancer Continues to Grow

Even with hormone therapy, prostate cancer eventually learns to grow despite very low testosterone levels. When this happens, doctors call it castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer. This doesn’t mean hormone therapy has completely stopped working or should be discontinued, but it does mean additional treatments are needed.^[5][16]

For castration-resistant disease, several options exist. If a man hasn’t already received one of the newer hormone drugs like enzalutamide or apalutamide, starting one of these may be very helpful. Another option is abiraterone acetate (brand name Zytiga), which blocks the body’s production of testosterone in a different way than standard hormone therapy. It prevents not just the testicles but also the adrenal glands and cancer cells themselves from making hormones that fuel cancer growth. Abiraterone is taken as pills daily along with prednisone.^[11][16]

Chemotherapy becomes an important option at this stage. Besides docetaxel, another chemotherapy drug called cabazitaxel (brand name Jevtana) may be used, particularly if docetaxel has stopped working or wasn’t tolerated well. Like docetaxel, cabazitaxel is given through IV infusion every three weeks, usually with prednisone.^[11]

A newer class of drugs called PARP inhibitors has become available for men whose cancer has specific genetic changes. PARP inhibitors, including olaparib (brand name Lynparza) and rucaparib (brand name Rubraca), work by blocking a protein that helps repair damaged DNA in cells. Cancer cells with mutations in genes like BRCA1, BRCA2, or other DNA repair genes are particularly vulnerable to PARP inhibitors because they already have trouble fixing their DNA. When the PARP protein is also blocked, the cancer cells can’t survive. These drugs are taken as pills daily and are used only after genetic testing confirms the presence of certain mutations.^[11][16]

A revolutionary treatment approach called lutetium-177 PSMA therapy (brand name Pluvicto) has recently been approved. This treatment combines imaging and therapy in an approach called theranostics. Most prostate cancer cells have large amounts of a protein called PSMA (prostate-specific membrane antigen) on their surface. Lutetium-177 PSMA therapy uses a radioactive substance attached to a molecule that seeks out and binds to PSMA. When it attaches to cancer cells, it delivers targeted radiation that kills the cells while causing less damage to surrounding healthy tissue. This treatment is given through IV infusion every six weeks for up to six doses. It’s typically used for men whose cancer has continued to grow despite treatment with newer hormone drugs and chemotherapy.^[9][15]

Promising Treatments Being Tested in Clinical Trials

Researchers are actively testing many new approaches to treating metastatic prostate cancer. Clinical trials are research studies that test whether new treatments are safe and effective. They happen in phases: Phase I trials test safety and determine the right dose in a small number of people, Phase II trials test whether the treatment works and gather more safety information in a larger group, and Phase III trials compare the new treatment to current standard treatments in hundreds or thousands of patients to see which works better.^[2]

One particularly exciting area of research involves bispecific T-cell engagers (BiTEs). These are engineered molecules that work like a bridge, connecting cancer cells to the body’s own immune T-cells. One end of the BiTE molecule attaches to a protein on the surface of prostate cancer cells (often PSMA), while the other end attaches to T-cells, bringing them into direct contact with the cancer. This activates the T-cells to attack and destroy the cancer cells. BiTEs represent a form of immunotherapy that harnesses the power of the immune system to fight cancer. Early studies have shown promising results, with some men experiencing significant shrinkage of their tumors.^[11]

Clinical trials are testing various combinations of existing drugs to see if using them together works better than using them separately. For example, researchers are studying whether combining PARP inhibitors with newer hormone drugs or with immunotherapy might be more effective than either treatment alone. The idea is that different drugs attack cancer through different mechanisms, and using them together might prevent the cancer from finding ways to resist treatment.^[11]

Immunotherapy has transformed treatment for many types of cancer, but its role in prostate cancer is still being defined. Unlike some other cancers, prostate cancer has been more difficult to treat with immunotherapy. However, researchers are testing checkpoint inhibitors like pembrolizumab (brand name Keytruda) in men whose tumors have specific characteristics that make them more likely to respond. These drugs work by removing the “brakes” that prevent the immune system from attacking cancer. Clinical trials are also testing cancer vaccines and other approaches to stimulate immune responses against prostate cancer.^[11][13]

One immunotherapy approach that has been approved is sipuleucel-T (brand name Provenge), though it’s used less commonly than some other treatments. This is a personalized vaccine created from each patient’s own immune cells. The cells are removed from the patient’s blood, sent to a laboratory where they’re exposed to a protein found in prostate cancer, and then returned to the patient through infusions. The goal is to train the immune system to recognize and attack prostate cancer cells. Three infusions are given over about a month.^[15]

Newer versions of PSMA-targeted therapies are being developed and tested. Beyond lutetium-177, researchers are exploring other radioactive isotopes that might be attached to PSMA-targeting molecules, potentially offering different advantages in terms of how deeply the radiation penetrates or how long it remains active. Trials are also testing whether PSMA-targeted therapies work better when given earlier in the disease course or in combination with other treatments.^[11]

Several trials are investigating new hormone therapies and drugs that target the pathways cancer cells use to grow and survive. These include medications that block specific molecular signals within cells, drugs that target the cancer’s ability to form new blood vessels (a process called angiogenesis), and agents that interfere with the cancer’s metabolism. Many of these experimental drugs have code names like “XYZ-123” during development before receiving official generic names.^[11]

Clinical trials are being conducted at cancer centers around the world, including in the United States, Europe, and many other countries. Eligibility for trials depends on many factors, including the stage and characteristics of the cancer, what treatments have been tried previously, the patient’s overall health, and specific genetic features of the tumor. Men interested in clinical trials should discuss options with their oncologist, who can help determine whether a trial might be appropriate and assist with finding and enrolling in suitable studies.^[2]

Most common treatment methods

• Hormone Therapy (Androgen Deprivation Therapy)
  • LHRH agonists like goserelin and leuprolide that suppress testosterone production through brain signaling
  • LHRH antagonists like degarelix that work faster to lower testosterone levels
  • Androgen receptor signaling inhibitors (ARSIs) including apalutamide, enzalutamide, and darolutamide that block testosterone from reaching cancer cells
  • Abiraterone acetate combined with prednisone that blocks testosterone production in multiple organs including adrenal glands and cancer cells
  • Surgical removal of testicles (orchiectomy) for permanent testosterone reduction
• Chemotherapy
  • Docetaxel given intravenously every three weeks, usually for six cycles, combined with prednisone
  • Cabazitaxel for men whose disease has progressed after docetaxel treatment
  • Often combined with hormone therapy in a triplet therapy approach for aggressive disease
• Radiation Therapy
  • External beam radiation to the prostate gland even when cancer has spread elsewhere
  • Targeted radiation to specific bone metastases for pain relief
  • Radium-223 dichloride (Xofigo) radioisotope therapy given through monthly IV injections for widespread bone metastases
• Targeted Therapy
  • PARP inhibitors (olaparib and rucaparib) for men with BRCA1, BRCA2, or other DNA repair gene mutations
  • Lutetium-177 PSMA therapy (Pluvicto) that delivers targeted radiation to cancer cells expressing PSMA protein
• Bone Protection Therapy
  • Bisphosphonates like zoledronic acid (Zometa) given as monthly infusions to strengthen bones
  • Denosumab (Xgeva) injections monthly to prevent fractures and reduce bone complications
• Immunotherapy
  • Sipuleucel-T (Provenge) personalized vaccine created from patient’s own immune cells
  • Checkpoint inhibitors being tested in clinical trials for specific patient populations
  • Bispecific T-cell engagers (BiTEs) under investigation that connect cancer cells to immune T-cells
• Supportive Care
  • Steroid medications like prednisone and dexamethasone for symptom control and inflammation reduction
  • Pain management strategies including medications and procedures for bone pain
  • Treatment for urinary and bowel complications